Tribulus Terrestris for Treatment of Sexual Dysfunction in Women: Randomized Double-blind Placebo - Controlled Study

Overview

Journal Daru

Specialty Pharmacology

Date 2014 Apr 30

PMID 24773615

Citations 17

Authors

Elham Akhtari

Firoozeh Raisi

Mansoor Keshavarz

Hamed Hosseini

Farnaz Sohrabvand

Soodabeh Bioos

Mohammad Kamalinejad

Ali Ghobadi

Affiliations

Soon will be listed here.

Abstract

Background: Tribulus terrestris as a herbal remedy has shown beneficial aphrodisiac effects in a number of animal and human experiments. This study was designed as a randomized double-blind placebo-controlled trial to assess the safety and efficacy of Tribulus terrestris in women with hypoactive sexual desire disorder during their fertile years. Sixty seven women with hypoactive sexual desire disorder were randomly assigned to Tribulus terrestris extract (7.5 mg/day) or placebo for 4 weeks. Desire, arousal, lubrication, orgasm, satisfaction, and pain were measured at baseline and after 4 weeks after the end of the treatment by using the Female Sexual Function Index (FSFI). Two groups were compared by repeated measurement ANOVA test.

Results: Thirty women in placebo group and thirty women in drug group completed the study. At the end of the fourth week, patients in the Tribulus terrestris group had experienced significant improvement in their total FSFI (p < 0.001), desire (p < 0.001), arousal (p = 0.037), lubrication (p < 0.001), satisfaction (p < 0.001) and pain (p = 0.041) domains of FSFI. Frequency of side effects was similar between the two groups.

Conclusions: Tribulus terrestris may safely and effectively improve desire in women with hypoactive sexual desire disorder. Further investigation of Tribulus terrestris in women is warranted.

Citing Articles

Placebo-controlled effect of topical Qust (Costus) oil on postmenopausal women's sexual desire disorder: a double-blind, randomized clinical trial.

Fallah A, Dabbaghian F, Jamshidi A, Akhtari E Eur J Transl Myol. 2024; 34(4.

PMID: 39286849 PMC: 11726170. DOI: 10.4081/ejtm.2024.12660.

Efficacy of an Oral Solution Containing Five Herbal Extracts in the Treatment of Urolithiasis: A Randomized, Single-blind, Placebo-controlled Clinical Trial.

Samandarian S, Soltani R, Hajhashemi V, Dehghani M, Matinfar M, Mahboubi M J Res Pharm Pract. 2024; 12(3):96-103.

PMID: 38716323 PMC: 11071061. DOI: 10.4103/jrpp.jrpp_11_24.

Is there a difference between the effects of phytoestrogens and non-phytoestrogens medicinal plants on sexual health? A systematic review and meta-analysis.

Sayahi M, Keramat A, Nourimand Ph D Candidate F, Mohammadzadeh H Int J Reprod Biomed. 2024; 21(11):881-900.

PMID: 38292511 PMC: 10823120. DOI: 10.18502/ijrm.v21i11.14652.

6-Week Supplementation with L. to Trained Male CrossFit Athletes on Muscle, Inflammation, and Antioxidant Biomarkers: A Randomized, Single-Blind, Placebo-Controlled Trial.

Fernandez-Lazaro D, Seco-Calvo J, Pascual-Fernandez J, Dominguez-Ortega C, Soto M, Mielgo-Ayuso J Int J Environ Res Public Health. 2022; 19(23).

PMID: 36498228 PMC: 9736311. DOI: 10.3390/ijerph192316158.

Effects of L. on Sport and Health Biomarkers in Physically Active Adult Males: A Systematic Review.

Fernandez-Lazaro D, Fernandez-Lazaro C, Seco-Calvo J, Garrosa E, Adams D, Mielgo-Ayuso J Int J Environ Res Public Health. 2022; 19(15).

PMID: 35954909 PMC: 9368143. DOI: 10.3390/ijerph19159533.

References

Basson R, Leiblum S, Brotto L, DeRogatis L, Fourcroy J, Fugl-Meyer K . Definitions of women's sexual dysfunction reconsidered: advocating expansion and revision. J Psychosom Obstet Gynaecol. 2004; 24(4):221-9. DOI: 10.3109/01674820309074686. View

Berman J, Berman L, Werbin T, Goldstein I . Female sexual dysfunction: anatomy, physiology, evaluation and treatment options. Curr Opin Urol. 2000; 9(6):563-8. DOI: 10.1097/00042307-199911000-00012. View

Clayton A . The pathophysiology of hypoactive sexual desire disorder in women. Int J Gynaecol Obstet. 2010; 110(1):7-11. DOI: 10.1016/j.ijgo.2010.02.014. View

Wiegel M, Meston C, Rosen R . The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005; 31(1):1-20. DOI: 10.1080/00926230590475206. View

Brotto L . The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Arch Sex Behav. 2009; 39(2):221-39. DOI: 10.1007/s10508-009-9543-1. View

Mazaro-Costa R, Andersen M, Hachul H, Tufik S . Medicinal plants as alternative treatments for female sexual dysfunction: utopian vision or possible treatment in climacteric women?. J Sex Med. 2010; 7(11):3695-714. DOI: 10.1111/j.1743-6109.2010.01987.x. View

Dennerstein L, Koochaki P, Barton I, Graziottin A . Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med. 2006; 3(2):212-22. DOI: 10.1111/j.1743-6109.2006.00215.x. View

Shifren J, Monz B, Russo P, Segreti A, Johannes C . Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008; 112(5):970-8. DOI: 10.1097/AOG.0b013e3181898cdb. View

Simon J . Opportunities for intervention in HSDD. J Fam Pract. 2009; 58(7 Suppl Hypoactive):S26-30. View

10.

Davis S, van der Mooren M, van Lunsen R, Lopes P, Ribot C, Ribot J . Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause. 2006; 13(3):387-96. DOI: 10.1097/01.gme.0000179049.08371.c7. View

11.

Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R . The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2000; 26(2):191-208. DOI: 10.1080/009262300278597. View

12.

Kashani L, Raisi F, Saroukhani S, Sohrabi H, Modabbernia A, Nasehi A . Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Hum Psychopharmacol. 2013; 28(1):54-60. DOI: 10.1002/hup.2282. View

13.

Safarinejad M . Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. Int J Impot Res. 2006; 18(4):382-95. DOI: 10.1038/sj.ijir.3901440. View

14.

Segraves R, Clayton A, Croft H, Wolf A, Warnock J . Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol. 2004; 24(3):339-42. DOI: 10.1097/01.jcp.0000125686.20338.c1. View

15.

Leiblum S, Koochaki P, Rodenberg C, Barton I, Rosen R . Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause. 2006; 13(1):46-56. DOI: 10.1097/01.gme.0000172596.76272.06. View

16.

Hayes R, Dennerstein L, Bennett C, Fairley C . What is the "true" prevalence of female sexual dysfunctions and does the way we assess these conditions have an impact?. J Sex Med. 2008; 5(4):777-787. DOI: 10.1111/j.1743-6109.2007.00768.x. View